ABIVAX Société Anonyme (ABVX)
NasdaqGM · USD · Healthcare · Biotechnology
$86.50 (-1.72%) as of
Key statistics
- Market cap
- 7.57B
- Forward P/E
- -22.55
- EPS (TTM)
- -6.08
- Dividend yield
- 0.00%
- 52-week range
- 69.81 – 148.83
- Beta
- -0.23
- Revenue (TTM)
- 4.67M
- Profit margin
- 0.00%
- Analyst target
- $163.58
- Volume
- 423.69k
About ABIVAX Société Anonyme
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Paris, France
- Employees
- 98
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.